Target Information
Target General Information | Top | |||||
---|---|---|---|---|---|---|
Target ID |
T23172
(Former ID: TTDC00084)
|
|||||
Target Name |
Janus kinase 3 (JAK-3)
|
|||||
Synonyms |
Tyrosine-protein kinase JAK3; Leukocyte janus kinase; L-JAK
|
|||||
Gene Name |
JAK3
|
|||||
Target Type |
Successful target
|
[1] | ||||
Disease | [+] 1 Target-related Diseases | + | ||||
1 | Rheumatoid arthritis [ICD-11: FA20] | |||||
Function |
Mediates essential signaling events in both innate and adaptive immunity and plays a crucial role in hematopoiesis during T-cells development. In the cytoplasm, plays a pivotal role in signal transduction via its association with type I receptors sharing the common subunit gamma such as IL2R, IL4R, IL7R, IL9R, IL15R and IL21R. Following ligand binding to cell surface receptors, phosphorylates specific tyrosine residues on the cytoplasmic tails of the receptor, creating docking sites for STATs proteins. Subsequently, phosphorylates the STATs proteins once they are recruited to the receptor. Phosphorylated STATs then form homodimer or heterodimers and translocate to the nucleus to activate gene transcription. For example, upon IL2R activation by IL2, JAK1 and JAK3 molecules bind to IL2R beta (IL2RB) and gamma chain (IL2RG) subunits inducing the tyrosine phosphorylation of both receptor subunits on their cytoplasmic domain. Then, STAT5A AND STAT5B are recruited, phosphorylated and activated by JAK1 and JAK3. Once activated, dimerized STAT5 translocates to the nucleus and promotes the transcription of specific target genes in a cytokine-specific fashion. Non-receptor tyrosine kinase involved in various processes such as cell growth, development, or differentiation.
Click to Show/Hide
|
|||||
BioChemical Class |
Kinase
|
|||||
UniProt ID | ||||||
EC Number |
EC 2.7.10.2
|
|||||
Sequence |
MAPPSEETPLIPQRSCSLLSTEAGALHVLLPARGPGPPQRLSFSFGDHLAEDLCVQAAKA
SGILPVYHSLFALATEDLSCWFPPSHIFSVEDASTQVLLYRIRFYFPNWFGLEKCHRFGL RKDLASAILDLPVLEHLFAQHRSDLVSGRLPVGLSLKEQGECLSLAVLDLARMAREQAQR PGELLKTVSYKACLPPSLRDLIQGLSFVTRRRIRRTVRRALRRVAACQADRHSLMAKYIM DLERLDPAGAAETFHVGLPGALGGHDGLGLLRVAGDGGIAWTQGEQEVLQPFCDFPEIVD ISIKQAPRVGPAGEHRLVTVTRTDNQILEAEFPGLPEALSFVALVDGYFRLTTDSQHFFC KEVAPPRLLEEVAEQCHGPITLDFAINKLKTGGSRPGSYVLRRSPQDFDSFLLTVCVQNP LGPDYKGCLIRRSPTGTFLLVGLSRPHSSLRELLATCWDGGLHVDGVAVTLTSCCIPRPK EKSNLIVVQRGHSPPTSSLVQPQSQYQLSQMTFHKIPADSLEWHENLGHGSFTKIYRGCR HEVVDGEARKTEVLLKVMDAKHKNCMESFLEAASLMSQVSYRHLVLLHGVCMAGDSTMVQ EFVHLGAIDMYLRKRGHLVPASWKLQVVKQLAYALNYLEDKGLPHGNVSARKVLLAREGA DGSPPFIKLSDPGVSPAVLSLEMLTDRIPWVAPECLREAQTLSLEADKWGFGATVWEVFS GVTMPISALDPAKKLQFYEDRQQLPAPKWTELALLIQQCMAYEPVQRPSFRAVIRDLNSL ISSDYELLSDPTPGALAPRDGLWNGAQLYACQDPTIFEERHLKYISQLGKGNFGSVELCR YDPLGDNTGALVAVKQLQHSGPDQQRDFQREIQILKALHSDFIVKYRGVSYGPGRQSLRL VMEYLPSGCLRDFLQRHRARLDASRLLLYSSQICKGMEYLGSRRCVHRDLAARNILVESE AHVKIADFGLAKLLPLDKDYYVVREPGQSPIFWYAPESLSDNIFSRQSDVWSFGVVLYEL FTYCDKSCSPSAEFLRMMGCERDVPALCRLLELLEEGQRLPAPPACPAEVHELMKLCWAP SPQDRPSFSALGPQLDMLWSGSRGCETHAFTAHPEGKHHSLSFS Click to Show/Hide
|
|||||
3D Structure | Click to Show 3D Structure of This Target | AlphaFold | ||||
HIT2.0 ID | T74QOR |
Drugs and Modes of Action | Top | |||||
---|---|---|---|---|---|---|
Approved Drug(s) | [+] 1 Approved Drugs | + | ||||
1 | Tofacitinib | Drug Info | Approved | Rheumatoid arthritis | [1], [2], [3] | |
Clinical Trial Drug(s) | [+] 7 Clinical Trial Drugs | + | ||||
1 | ASP-015K | Drug Info | Phase 3 | Psoriasis vulgaris | [4], [5] | |
2 | PF-06651600 | Drug Info | Phase 2/3 | Alopecia | [6] | |
3 | VX-509 | Drug Info | Phase 2/3 | Rheumatoid arthritis | [7], [8] | |
4 | ATI-501 | Drug Info | Phase 2 | Alopecia | [9] | |
5 | ATI-502 | Drug Info | Phase 2 | Atopic dermatitis | [10] | |
6 | Cerdulatinib | Drug Info | Phase 2 | B-cell lymphoma | [11] | |
7 | SNA-125 | Drug Info | Phase 1 | Atopic dermatitis | [12] | |
Discontinued Drug(s) | [+] 3 Discontinued Drugs | + | ||||
1 | AG490 | Drug Info | Terminated | Multiple myeloma | [13], [14] | |
2 | PNU156804 | Drug Info | Terminated | Renal transplantation | [15] | |
3 | R348 | Drug Info | Terminated | Psoriasis vulgaris | [16] | |
Mode of Action | [+] 2 Modes of Action | + | ||||
Modulator | [+] 1 Modulator drugs | + | ||||
1 | Tofacitinib | Drug Info | [1] | |||
Inhibitor | [+] 87 Inhibitor drugs | + | ||||
1 | ASP-015K | Drug Info | [17] | |||
2 | PF-06651600 | Drug Info | [12] | |||
3 | VX-509 | Drug Info | [18], [19] | |||
4 | ATI-501 | Drug Info | [20] | |||
5 | ATI-502 | Drug Info | [10] | |||
6 | Cerdulatinib | Drug Info | [12] | |||
7 | SNA-125 | Drug Info | [12] | |||
8 | 1,2,4-triazolo[1,5a]pyridine derivative 1 | Drug Info | [21] | |||
9 | Aminooxazole carboxamide derivative 1 | Drug Info | [22] | |||
10 | Aminotriazolopyridine derivative 1 | Drug Info | [21] | |||
11 | Benzimidazole derivative 5 | Drug Info | [22] | |||
12 | Benzimidazole derivative 7 | Drug Info | [21] | |||
13 | Bis-aminopyrimidine derivative 1 | Drug Info | [21] | |||
14 | Bis-aminopyrimidine derivative 2 | Drug Info | [21] | |||
15 | Bis-aminopyrimidine derivative 3 | Drug Info | [21] | |||
16 | Bis-aminopyrimidine derivative 4 | Drug Info | [21] | |||
17 | Five-and-six-membered heterocyclic compound 1 | Drug Info | [22] | |||
18 | Imidazopyridazine derivative 1 | Drug Info | [21] | |||
19 | Imidazopyridazine derivative 2 | Drug Info | [21] | |||
20 | Imidazopyridine derivative 4 | Drug Info | [21] | |||
21 | Imidazo[4,5-c]pyridine derivative 1 | Drug Info | [21] | |||
22 | Imidazo[4,5-c]pyridine derivative 2 | Drug Info | [21] | |||
23 | Isoxazole derivative 1 | Drug Info | [22] | |||
24 | Isoxazole derivative 2 | Drug Info | [22] | |||
25 | N-(cyanomethyl)-4-(2-(phenylamino)pyrimidin-4-yl)benzamide derivative 1 | Drug Info | [21] | |||
26 | N-methylmethanesulfonamide derivative 1 | Drug Info | [22] | |||
27 | PMID27774822-Compound-Figure10Example1 | Drug Info | [22] | |||
28 | PMID27774822-Compound-Figure10Example19 | Drug Info | [22] | |||
29 | PMID27774822-Compound-Figure11Example5 | Drug Info | [22] | |||
30 | PMID27774822-Compound-Figure1Example20 | Drug Info | [22] | |||
31 | PMID27774822-Compound-Figure2Example1-1left | Drug Info | [22] | |||
32 | PMID27774822-Compound-Figure2Example1-1right | Drug Info | [22] | |||
33 | PMID27774822-Compound-Figure2Example4-3 | Drug Info | [22] | |||
34 | PMID27774822-Compound-Figure6Example2 | Drug Info | [22] | |||
35 | PMID27774822-Compound-Figure6Example3 | Drug Info | [22] | |||
36 | PMID27774822-Compound-Figure8Example5 | Drug Info | [22] | |||
37 | PMID27774824-Compound-Figure11Example1up | Drug Info | [21] | |||
38 | PMID27774824-Compound-Figure12Example1 | Drug Info | [21] | |||
39 | PMID27774824-Compound-Figure12Example10 | Drug Info | [21] | |||
40 | PMID27774824-Compound-Figure12Example61 | Drug Info | [21] | |||
41 | PMID27774824-Compound-Figure2Example4 | Drug Info | [21] | |||
42 | PMID27774824-Compound-Figure3Example18 | Drug Info | [21] | |||
43 | PMID27774824-Compound-Figure3Example7 | Drug Info | [21] | |||
44 | PMID27774824-Compound-Figure5Example13 | Drug Info | [21] | |||
45 | PMID27774824-Compound-Figure6Example12 | Drug Info | [21] | |||
46 | PMID27774824-Compound-Figure9Example2down | Drug Info | [21] | |||
47 | PMID27774824-Compound-Figure9Example2up | Drug Info | [21] | |||
48 | Pyrazolopyridine derivative 1 | Drug Info | [22] | |||
49 | Pyrazolopyridine derivative 2 | Drug Info | [22] | |||
50 | Pyrazolopyridine derivative 3 | Drug Info | [22] | |||
51 | Pyrazolopyridine derivative 4 | Drug Info | [22] | |||
52 | Pyrazolopyridine derivative 6 | Drug Info | [21] | |||
53 | Pyrazolopyridine derivative 7 | Drug Info | [21] | |||
54 | Pyrazolo[4,3-c]pyridine derivative 2 | Drug Info | [21] | |||
55 | Pyrimidopyridazinone derivative 2 | Drug Info | [21] | |||
56 | Pyrrole six-membered heteroaryl ring derivative 1 | Drug Info | [22] | |||
57 | Pyrrolo-pyrazine derivative 1 | Drug Info | [22] | |||
58 | Pyrrolo-pyrazine derivative 2 | Drug Info | [22] | |||
59 | Pyrrolo-pyrazine derivative 3 | Drug Info | [22] | |||
60 | Pyrrolo-pyrazine derivative 4 | Drug Info | [22] | |||
61 | Pyrrolo-pyridine derivative 3 | Drug Info | [22] | |||
62 | Pyrrolo[2,3-d]pyrimidine derivative 6 | Drug Info | [22] | |||
63 | Pyrrolo[2,3-d]pyrimidine derivative 7 | Drug Info | [22] | |||
64 | Pyrrolo[2,3-d]pyrimidine derivative 8 | Drug Info | [22] | |||
65 | Ruxolitinib derivative 2 | Drug Info | [21] | |||
66 | Tricyclic compound 1 | Drug Info | [21] | |||
67 | Tricyclic compound 11 | Drug Info | [22] | |||
68 | Tricyclic compound 2 | Drug Info | [21] | |||
69 | Tricyclic heterocycle derivative 1 | Drug Info | [22] | |||
70 | Tricyclic heterocycle derivative 2 | Drug Info | [21] | |||
71 | Tricyclic heterocycle derivative 5 | Drug Info | [22] | |||
72 | Tricyclic pyrrolopyridine compound 1 | Drug Info | [22] | |||
73 | AG490 | Drug Info | [23] | |||
74 | PNU156804 | Drug Info | [24] | |||
75 | R348 | Drug Info | [16] | |||
76 | 6-o-tolylquinazolin-2-amine | Drug Info | [25] | |||
77 | AD-412 | Drug Info | [17] | |||
78 | Atropisomer 1 | Drug Info | [26] | |||
79 | CMP-6 | Drug Info | [27] | |||
80 | NC1153 | Drug Info | [23] | |||
81 | PF-956980 | Drug Info | [17] | |||
82 | PMID15546730C2 | Drug Info | [28] | |||
83 | PMID21493067C1d | Drug Info | [29] | |||
84 | PMID24359159C19a | Drug Info | [30] | |||
85 | VX-467 | Drug Info | [17] | |||
86 | WHI-P154 | Drug Info | [31] | |||
87 | ZM-39923 | Drug Info | [32] |
Chemical Structure based Activity Landscape of Target | Top |
---|---|
Drug Property Profile of Target | Top | |
---|---|---|
(1) Molecular Weight (mw) based Drug Clustering | (2) Octanol/Water Partition Coefficient (xlogp) based Drug Clustering | |
|
||
(3) Hydrogen Bond Donor Count (hbonddonor) based Drug Clustering | (4) Hydrogen Bond Acceptor Count (hbondacc) based Drug Clustering | |
|
||
(5) Rotatable Bond Count (rotbonds) based Drug Clustering | (6) Topological Polar Surface Area (polararea) based Drug Clustering | |
|
||
"RO5" indicates the cutoff set by lipinski's rule of five; "D123AB" colored in GREEN denotes the no violation of any cutoff in lipinski's rule of five; "D123AB" colored in PURPLE refers to the violation of only one cutoff in lipinski's rule of five; "D123AB" colored in BLACK represents the violation of more than one cutoffs in lipinski's rule of five |
Co-Targets | Top | |||||
---|---|---|---|---|---|---|
Co-Targets |
Target Poor or Non Binders | Top | |||||
---|---|---|---|---|---|---|
Target Poor or Non Binders |
Target Regulators | Top | |||||
---|---|---|---|---|---|---|
Target-regulating microRNAs | ||||||
Target-interacting Proteins |
Target Profiles in Patients | Top | |||||
---|---|---|---|---|---|---|
Target Expression Profile (TEP) |
Target-Related Models and Studies | Top | |||||
---|---|---|---|---|---|---|
Target Validation |
References | Top | |||||
---|---|---|---|---|---|---|
REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||||
REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5677). | |||||
REF 3 | ClinicalTrials.gov (NCT02157012) Evaluation of the Condition of Rheumatoid Arthritis After Treatment. U.S. National Institutes of Health. | |||||
REF 4 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8315). | |||||
REF 5 | ClinicalTrials.gov (NCT02308163) A Study to Evaluate Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to DMARDs. U.S. National Institutes of Health. | |||||
REF 6 | ClinicalTrials.gov (NCT03732807) PF-06651600 for the Treatment of Alopecia Areata (ALLEGRO-2b/3). U.S. National Institutes of Health. | |||||
REF 7 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8309). | |||||
REF 8 | ClinicalTrials.gov (NCT01830985) A Phase 2/3 Open-label Extension Study to Evaluate Long-Term Safety and Efficacy With VX-509 in Subjects With Rheumatoid Arthritis. U.S. National Institutes of Health. | |||||
REF 9 | ClinicalTrials.gov (NCT03594227) ATI-501 Oral Suspension Compared to Placebo in Subjects With Alopecia Areata, Alopecia Universalis or Alopecia Totalis. U.S. National Institutes of Health. | |||||
REF 10 | ClinicalTrials.gov (NCT03759340) ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT). U.S. National Institutes of Health. | |||||
REF 11 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
REF 12 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
REF 13 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5916). | |||||
REF 14 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006610) | |||||
REF 15 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008393) | |||||
REF 16 | Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63. | |||||
REF 17 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2049). | |||||
REF 18 | Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77. | |||||
REF 19 | VX-509 (decernotinib) is a potent and selective janus kinase 3 inhibitor that attenuates inflammation in animal models of autoimmune disease. J Pharmacol Exp Ther. 2015 May;353(2):405-14. | |||||
REF 20 | Clinical pipeline report, company report or official report of Aclaris Therapeutics. | |||||
REF 21 | Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. | |||||
REF 22 | Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. | |||||
REF 23 | Immunotherapy for De Novo renal transplantation: what's in the pipeline Drugs. 2006;66(13):1665-84. | |||||
REF 24 | Selective inhibitor of Janus tyrosine kinase 3, PNU156804, prolongs allograft survival and acts synergistically with cyclosporine but additively with rapamycin. Blood. 2002 Jan 15;99(2):680-9. | |||||
REF 25 | Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activity. J Med Chem. 2006 Sep 21;49(19):5671-86. | |||||
REF 26 | Janus kinase 2 inhibitors. Synthesis and characterization of a novel polycyclic azaindole. J Med Chem. 2009 Dec 24;52(24):7938-41. | |||||
REF 27 | Photochemical preparation of a pyridone containing tetracycle: a Jak protein kinase inhibitor. Bioorg Med Chem Lett. 2002 Apr 22;12(8):1219-23. | |||||
REF 28 | Discovery of novel 2-(aminoheteroaryl)-thiazole-5-carboxamides as potent and orally active Src-family kinase p56(Lck) inhibitors. Bioorg Med Chem Lett. 2004 Dec 20;14(24):6061-6. | |||||
REF 29 | In vitro and in vivo evaluation of 6-aminopyrazolyl-pyridine-3-carbonitriles as JAK2 kinase inhibitors. Bioorg Med Chem Lett. 2011 May 15;21(10):2958-61. | |||||
REF 30 | Discovery of 1-methyl-1H-imidazole derivatives as potent Jak2 inhibitors. J Med Chem. 2014 Jan 9;57(1):144-58. | |||||
REF 31 | The specificity of JAK3 kinase inhibitors. Blood. 2008 Feb 15;111(4):2155-7. | |||||
REF 32 | Naphthyl ketones: a new class of Janus kinase 3 inhibitors. Bioorg Med Chem Lett. 2000 Mar 20;10(6):575-9. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.